An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
About this study
This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care. The goal of this study is to learn more about the use, benefits, and safety of cemiplimab based treatment regimens in participants with NSCLC.
- Condition
- Non-small Cell Lung Cancer
- Tested
- Cemiplimab, Platinum-based chemotherapy
- Sponsor
- Regeneron Pharmaceuticals
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Study condition: Non-small Cell Lung Cancer
- At least 18 years of age at the time of cemiplimab treatment initiation
- Has been diagnosed with histologically or cytologically documented squamous or non-squamous NSCLC
- Prescribed a cemiplimab-based regimen as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the Summary of Product Characteristics (SmPC).
- Can understand and complete the study-related questionnaires
- Must be legally capable of providing written consent for participation in the study and have signed informed consent prior to any study activities
Exclusion 6
- Has received cemiplimab prior to enrollment
- Has uncontrolled autoimmune disease
- Has a contraindication to cemiplimab as noted in the local SmPC
- Is concurrently participating in any other study of an investigational drug or procedure
- Has cognitive impairment or other medical condition that, in the opinion of the investigator, would interfere with the ability to complete the study-related questionnaires
- NOTE: Other protocol-defined inclusion/exclusion criteria apply
Where
49 sites, 44 recruiting
Klinikum Klagenfurt
Klagenfurt, Carinthia, Austria
Salzburger Landeskliniken (SALK)
Salzburg, Austria
Centre Hospitalier Universitaire Angers
Angers, France
Sainte Catherine Institut du Cancer Avignon Provence
Avignon, Vaucluse, France
Centre Hospitalier - Le mans
Le Mans, France
APHM - Hopital Nord
Marseille, Bouches-du-Rhône, France
and 43 more sites on ClinicalTrials.gov
Contact
-
Clinical Trials Administrator
844-734-6643 clinicaltrials@regeneron.com
Potential match only. Final eligibility is determined by the study team.